NCT06487039View on ClinicalTrials.gov

Trial to Evaluate the Safety and Efficacy of EB-203 in Patients With Neovascular Age-related Macular Degeneration

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

August 31, 2025

Study Completion Date

January 31, 2026

Conditions
Neovascular Age-related Macular Degeneration (nAMD)
Interventions
DRUG

EB-203

Subjects will receive EB-203 according to the following dosage and administration method for each treatment group.

Trial Locations (5)

42415

RECRUITING

Yeungnam University Medical Center, Daegu

47392

RECRUITING

Busan Paik Hospital, Inje University, Busan

49241

RECRUITING

Pusan National University Hospital, Busan

08858

RECRUITING

Kim's Eye Hospital, Seoul

RECRUITING

Seoul National University Hospital, Seoul

All Listed Sponsors
lead

EyebioKorea, Inc.

INDUSTRY